In non-small cell lung cancer, breast cancer, and head and neck cancer, high SEC62 expression correlated with a significantly shorter overall survival, and the occurrence of lymph node and/or distant metastases [17,19,20,21]. This evidence concerns the gene SEC62 and breast cancer.